Biomea Fusion, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Biomea Fusion, Inc. (BMEA) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $5.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-05
- Biomea Fusion, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-03-31 was $5.00K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month |
|---|---|
| 2025-03-31 | $5.00K 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |